Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


DHEA bill returns

This article was originally published in The Tan Sheet

Executive Summary

Sen. Chuck Grassley, R-Iowa, on March 5 reintroduces a bill to list dehydroepiandrosterone as an anabolic steroid under the Controlled Substances Act. Co-sponsored by Sens. Dick Durbin, D-Ill. and John McCain, R-Ariz., S. 762 has been referred to the Judiciary Committee. In a same day release, Grassley says DHEA has "a number of potential long-term physical and psychological effects" including heart disease, cancer, stroke and liver damage. Industry groups maintain DHEA has little to no potential for abuse. Grassley previously introduced the measure in 2005 (1"The Tan Sheet" June 6, 2005, p. 11)...

You may also be interested in...

DHEA Debate Returns To Fore: Anabolic Steroid Status Sought In Grassley Bill

A new bill sponsored by Sen. Charles Grassley (R-Iowa) would regulate dehydroepiandrosterone (DHEA) as an anabolic steroid under the Controlled Substances Act

PCPC Exploring Solutions With Chinese Authorities To Facilitate Cruelty-Free Cosmetic Imports

France plans to begin issuing manufacturing quality certificates so firms can import ordinary cosmetics into China without animal testing under a 2020 draft regulation. The Personal Care Products Council is working to find a comparable solution for US manufacturers.

Aurinia Launches Its First Drug With Lupkynis Approval For Lupus Nephritis

The calcineurin inhibitor, only the second drug to be approved by the US FDA for lupus nephritis, will be competing against GlaxoSmithKline’s Benlysta.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts